Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum


Manage episode 332499180 series 103449
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Summarize the current roles, mechanisms of action, and key evidence pertaining to novel systemic therapies for patients with localized or metastatic bladder cancer, such as immunotherapies, small molecule targeted therapies, and antibody-drug conjugates, among others, Plan personalized treatment algorithms for patients with localized or metastatic urothelial cancer that incorporate novel and emerging therapies, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Implement evidence-based strategies and expert recommendations to prevent, mitigate and/or manage treatment-related adverse events that may occur among patients receiving novel systemic therapies for bladder cancer.

967 episodes